Maged Shenouda insider trades: Relmada Therapeutics (RLMD) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Maged reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | RLMD | ↑ Buy | 200,000 | $4.22 | $844K | Direct | Sep 11, 2026 (1d) |
| Dec 15, 2025 | RLMD | ↑ Buy | 11,665 | $4.12 | $48K | Direct | Dec 16, 2025 (1d) |
| Nov 5, 2025 | RLMD | ↑ Buy | 500,000 | $2.20 | $1.1M | Direct | Nov 6, 2025 (1d) |
| May 20, 2025 | RLMD | ↑ Buy | 200,000 | $0.49 | $97K | Direct | May 20, 2025 (0d) |
| Sep 11, 2024 | RLMD | ↑ Buy | 53,432 | $2.80 | $150K | Direct | Sep 11, 2024 (0d) |
| Jan 31, 2024 | RLMD | ↑ Buy | 32,675 | $3.85 | $126K | Direct | Jan 31, 2024 (0d) |
| Mar 10, 2021 | RLMD | ↓ Sell | 10,000 | $35.45 | $355K | Direct | Mar 10, 2021 (0d) |
| Feb 24, 2021 | RLMD | ↓ Sell | 3,000 | $34.18 | $103K | Direct | Feb 26, 2021 (2d) |
| Feb 11, 2021 | RLMD | ↓ Sell | 1,428 | $35.39 | $51K | Direct | Feb 16, 2021 (5d) |
| Feb 10, 2021 | RLMD | ↓ Sell | 11,372 | $35.17 | $400K | Direct | Feb 10, 2021 (0d) |
| Feb 3, 2021 | RLMD | ↓ Sell | 3,200 | $35.04 | $112K | Direct | Feb 4, 2021 (1d) |
| Jan 27, 2021 | RLMD | ↓ Sell | 3,000 | $31.93 | $96K | Direct | Jan 29, 2021 (2d) |
| Jan 26, 2021 | RLMD | ↓ Sell | 4,000 | $35.40 | $142K | Direct | Jan 26, 2021 (0d) |
| Oct 21, 2019 | RLMD | ↑ Buy | 978 | $23.00 | $22K | Direct | Oct 21, 2019 (0d) |
| Dec 28, 2018 | AZRX | ↑ Buy | 20,000 | $1.31 | $26K | Direct | Jan 2, 2019 (5d) |
| Dec 15, 2015 | RLMD | ↑ Buy | 3,000 | $2.99 | $9K | Direct | Dec 17, 2015 (2d) |
| Dec 14, 2015 | RLMD | ↑ Buy | 2,000 | $2.89 | $6K | Direct | Dec 16, 2015 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RLMD insiders
Open-market trades in the last 12 months
About Maged Shenouda's insider trades
Maged Shenouda is Chief Financial Officer at Relmada Therapeutics (RLMD). Since Dec 14, 2015, Maged has reported 10 open-market purchases worth $2.4M and 7 sales worth $1.3M on SEC Form 4. In the last 12 months: 2 buys ($892K).
Their filings also include grants and awards (18 filings), option exercises (7 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RLMD insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.